Literature DB >> 7586162

N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors.

B P Sani1, Y F Shealy, D L Hill.   

Abstract

The cellular transport, metabolism and biological activity of retinoids are mediated by their specific binding proteins and nuclear receptors. For an understanding of the mode of action of retinoids with potential cancer chemopreventive or other biological activity, it is important to study their interactions with these binding proteins and receptors. In our attempts to understand the action of N-(4-hydroxyphenyl)retinamide (4HPR) and other retinamides in the prevention of cancer, we observed that 4HPR binds to a serum protein with a molecular size of approximately 20,000. The retinoid, however, did not show any binding affinity for cellular retinol-binding protein (CRABP) or for cellular retinoic acid-binding protein (CRABP). However, it showed binding affinity for the nuclear receptors of retinoic acid (RARs) equivalent to 15% of that of retinoic acid. The physicochemical properties of the 4HPR binding protein in the serum were identical to those of serum retinol binding protein (RBP). Antibodies against RBP quantitatively immunoprecipitated the protein-4HPR complex, confirming that the retinoid specifically binds to RBP. Although retinol and 4HPR cross-competed for RBP binding, N-phenylretinamide, in which the 4-hydroxyl group is absent, and N-(4-methoxyphenyl)retinamide, a major cellular metabolite of 4HPR, in which the hydroxyl group is blocked, did not show affinity for the binding protein. The results indicate that the hydroxyl group of 4HPR is essential for binding of this type of retinoid to RBP. Thus, our studies suggest that serum transport of 4HPR may be facilitated by RBP. To bind more efficiently to CRBP, CRABP, or RARs/RXRs, the retinoid may require further metabolic change.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586162     DOI: 10.1093/carcin/16.10.2531

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.

Authors:  Serena M Mershon; Allyson L Anding; Jason S Chapman; Margaret Clagett-Dame; Laura A Stonerock; Robert W Curley
Journal:  Bioorg Med Chem Lett       Date:  2006-10-25       Impact factor: 2.823

2.  Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Barry J Maurer; C Patrick Reynolds; Min Kang; Hardeep Singh; Sonja Crandon; Anthony J Murgo; James H Doroshow
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

Review 3.  Cancer treatment strategies targeting sphingolipid metabolism.

Authors:  Babak Oskouian; Julie D Saba
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.

Authors:  Hwang Eui Cho; H Kang Min
Journal:  J Pharm Biomed Anal       Date:  2016-09-29       Impact factor: 3.935

Review 5.  Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.

Authors:  C P Reynolds
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

Review 6.  Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule.

Authors:  Rosa Luisa Potenza; Pietro Lodeserto; Isabella Orienti
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

7.  Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells.

Authors:  Manrong Jiang; Kejin Zhu; Jose Grenet; Jill M Lahti
Journal:  Biochim Biophys Acta       Date:  2008-03-10

8.  The Retinoic Acid Receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production.

Authors:  Harry D Dawson; Gary Collins; Robert Pyle; Michael Key; Dennis D Taub
Journal:  BMC Immunol       Date:  2008-04-16       Impact factor: 3.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.